Business Wire

SAMSUNG-ELECTRONICS

19.5.2020 09:02:14 CEST | Business Wire | Press release

Share
Samsung Introduces 1.2μm 50Mp ISOCELL GN1 with Faster Auto-focusing and Brighter Images

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN1, a new 50-megapixel (Mp) image sensor with large 1.2μm-sized pixels. The ISOCELL GN1 is Samsung’s first image sensor to offer both Dual Pixel and Tetracell technologies. Thanks to the relatively larger pixel size, the GN1 brings image sensor performance to a new level with a combination of elevated light sensitivity for stellar low-light photos and DSLR-level auto-focus speeds, optimized for more dynamic picture-taking experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005376/en/

“With innovative pixel technologies, Samsung has been at the forefront of offering high-performance image sensors that closely cater to increasingly diversifying market needs. The ISOCELL GN1 is part of that commitment to deliver stunning images to consumers in any environment,” said Yongin Park, executive vice president of sensor business at Samsung Electronics. “We will continue to introduce image sensor solutions at the cutting-edge that will lead the next trends in mobile photography.”

Creating desirable images is an indispensable element for today’s smartphone users who are well accustomed to visually grasping and cherishing special moments, wherever they are. To address various imaging preferences of the users, some smartphone makers put more emphasis on extremely detailed images with ultra-high resolutions, while some choose bigger pixels for bright results in low-light environments. The new Samsung ISOCELL GN1 fulfills these multiple needs at once with Dual Pixel and Tetracell technologies.

The GN1 brings best-in-class auto-focusing with 100 million phase detection auto-focus (PDAF) agents. Samsung’s Dual Pixel technology places two photodiodes side-by-side within a single pixel that can receive light from different angles for phase detection. With all of the sensor’s active pixels working as auto-focusing agents, the GN1 can detect and focus onto a desired still or moving object from every corner in an instant, even in low-light conditions. When capturing images, a single pixel output is created by merging the outputs from the two photodiodes within the pixel. Samsung also provides a software algorithm that takes light information from each photodiode to produce image resolutions comparable to 100Mp.

For ultimate low-light photography, the GN1 adopts Tetracell technology, a pixel-merging technique that improves the pixels’ capacity to capture and process more light. By binning four pixel signals into one, Tetracell doubles the image sensor’s pixel size to 2.4μm and quadruples the light sensitivity to take brighter 12.5Mp photographs. With improved light sensitivity combined with a powerful auto-focusing solution, the GN1 is able to focus on an object quickly even in extreme low-light environment to deliver both brighter and sharper results.

In addition to Dual Pixel and Tetracell technologies, the GN1 comes with Smart-ISO that intelligently selects the optimal ISO, real-time HDR that captures the scene in multiple exposures simultaneously, and gyro-based electronic image stabilization (EIS) that takes sharp images and video even when in motion. For premium video quality, the image sensor supports video recording at up to 8K resolution at 30 frames-per-second (fps).

Samsung ISOCELL GN1 started mass production this month.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye